FDA has granted Fast Track designation to tipifarnib for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
